Brief: Medicinova Announces Health Canada Grants Authorization To Commence Multi-arm Phase 2/3 Clinical Trial To Evaluate MN-166 (ibudilast) In Long COVID
08/02/2023 23:38
Feb 8 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES HEALTH CANADA GRANTS AUTHORIZATION TO
COMMENCE MULTI-ARM PHASE 2/3 CLINICAL TRIAL TO EVALUATE MN-166
(IBUDILAST) IN LONG COVID
Source text for Eikon: ID:nGNX6zbbnL
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake